More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B....

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On a regional basis, gains in the Western Hemisphere and Asia-Pacific Africa helped to offset a 3.4% decline of revenue in Europe. Sees full-year 2012 EPS of $5.05-$5.10, lower than prior guidance of $5.00-$5.07 and the consensus mark of analysts calling for $5.06. Shares +1.2% premarket. (PR)